Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
November 14, 2005
- AstraZeneca to Support Lung Cancer Awareness
November 14, 2005
- Takeda: Ethical Drug Sales Up 8.8% at \500,900 Mil.
November 14, 2005
- Eisai: Record Sales, Profits; Overseas Sales Break 50%
November 14, 2005
- Santen: Ethical Drugs Drive Growth in Sales, Profits
November 14, 2005
- Torii: Sales, Profits Hit by Slump in Major Products, TachoComb Transfer
November 14, 2005
- Japan Tobacco: Pharma Division Sales Down 0.8%
November 14, 2005
- President Dr Aoki Outlines JPMA's Stance on NHI Pricing
November 14, 2005
- Teijin: Sales of Medical and Pharmaceuticals Business Rise 8.8% to Top \51,600 Mil.
November 14, 2005
- Jiro Kawasaki Appointed Minister of Health, Labor and Welfare
November 14, 2005
- Wyeth's Anticancer Drug Pipeline Outlined
November 14, 2005
- Korosho Political Tribe Concerned about Intimacy between Mr Kawasaki and Mr Tanigaki
November 14, 2005
- OPINION
November 14, 2005
- Council Members Insist on Deep Cuts into Medical Fees, NHI Prices
November 14, 2005
- Japanese Physicians Should More Positively Approach New Drug Development: Lilly's CMO A. Breier
November 14, 2005
- Reformists Criticize Korosho's Healthcare Reform Proposals
November 14, 2005
- Council Calls For Early Approval of 5 Global Standard Drugs Not Approved in Japan
November 14, 2005
- Health Economics Status Survey: Pharmacies' Profits Rose 7.6%
November 14, 2005
- R&D NEWS IN BREIF
November 14, 2005
- REGULATORY NEWS IN BRIEF
November 7, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…